No FDA- or EMA-approved medication addresses the fact that CCR2 contributes to the migration of immune cells and, in some cases, provides an alternative route to HIV infection (85), which potentially augments the clinical importance of targeting CCR2. The gene discussed is CCR2; the disease is HIV infectious disease.